FrancophonIA/ELRC3.0 huggingface dataset:
English: Sprimeo in combination with an ACE inhibitor or an ARB must not be used in patients with diabetes, or moderate or severe kidney impairment.
Estonian: Sprimeot ei tohi kasutada koos ACE-inhibiitori ega ARB-ga, kui patsiendil on diabeet või mõõdukas kuni raske neerukahjustus.
English: The medicine can only be obtained with a prescription.
Estonian: Sprimeo on retseptiravim.
English: Sprimeo on its own was more effective than placebo and as effective as comparator treatments in reducing blood pressure.
Estonian: Sprimeo vähendas kasutamisel ainsa ravimina vererõhku efektiivsemini kui platseebo ja sama efektiivselt kui võrdlusravimid.
English: The CHMP noted that Sprimeo is effective in reducing blood pressure when used alone or in combination.
Estonian: Inimravimite komitee märkis, et Sprimeo on vererõhu alandamisel efektiivne ainuravimina või koos teiste ravimitega.
English: However, in February 2012, following the review of a study called ALTITUDE, the CHMP recommended that Sprimeo should not be used together with an ACE inhibitor or ARB in patients with diabetes or with moderate or severe kidney impairment because of an increase in the risk of cardiovascular and kidney problems.
Estonian: tulemuste läbivaatamist soovitas inimravimite komitee Sprimeot mitte kasutada koos ACE-inhibiitori ega ARB-ga patsientidel, kellel on diabeet või mõõdukas kuni raske neerukahjustus, sest ravim suurendab kardiovaskulaarsete ja neeruhäirete suurenemise riski.
English: How has Sprimeo been studied?
Estonian: Kuidas Sprimeot uuriti?
English: How does Sprimeo work?
Estonian: Kuidas Sprimeo toimib?
English: The dose of Sprimeo may be increased to 300 mg once a day in patients whose blood pressure is not adequately controlled.
Estonian: Patsientidel, kelle vererõhk ei allu ravile piisavalt, võib Sprimeo annust suurendada annuseni 300 mg üks kord ööpäevas.
English: Larger falls were seen in patients aged 65 years or over and those taking higher doses of Sprimeo.
Estonian: Vähemalt 65-aastastel patsientidel ja Sprimeot suuremates annustes kasutanud patsientidel vähenes vererõhk rohkem.
English: They are available in Austria, Belgium, Bulgaria, Czech Republic, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovakia and Slovenia.
Estonian: Neid turustatakse Austrias, Belgias, Bulgaarias, Itaalias, Kreekas, Leedus, Luksemburgis, Lätis, Maltal, Poolas, Portugalis, Rumeenias, Saksamaal, Slovakkias, Sloveenias, Tšehhi Vabariigis ja Ungaris.
English: The CHMP opinion was forwarded to the European Commission, which issued a final legally binding decision applicable in all EU Member States on 09 September 2019.
Estonian: Inimravimite komitee arvamus edastati Euroopa Komisjonile, kes tegi 9. septembril 2019 lõpliku õiguslikult siduva otsuse, mida kohaldatakse kõigis Euroopa Liidu liikmesriikides.
English: The review of bacterial lysate medicines was initiated on 28 June 2018 at the request of Italy, under Article 31 of Directive 2001/83/EC.
Estonian: 28. juunil 2018 algatati Itaalia taotlusel bakterilüsaadipõhiste ravimite direktiivi 2001/83/EÜ artikli 31 kohane läbivaatamine.
English: They are sold under several brand names including Broncho Munal, Broncho Vaxom, Buccalin, Immubron, Immucytal, Ismigen, Lantigen B, Luivac, Ommunal, Paspat, Pir-05, Polyvaccinum, Provax, Respivax and Ribomunyl.
Estonian: Neid müüakse eri kaubamärkide all, sealhulgas Broncho Munal, Broncho Vaxom, Buccalin, Immubron, Immucytal, Ismigen, Lantigen B, Luivac, Ommunal, Paspat, Pir-05, Polyvaccinum, Provax, Respivax ja Ribomunyl.
English: • If you have any questions or concerns about your medicine, discuss them with your doctor or pharmacist.
Estonian: • Kui teil on oma ravimiga seoses küsimusi või probleeme, pöörduge oma arsti või apteekri poole.
English: Bacterial lysate medicines have been authorised via national procedures.
Estonian: Bakterilüsaadipõhised ravimid on saanud müügiloa riiklike menetluste kaudu.
English: The CHMP therefore recommended that use of the medicines for prevention can continue, but the companies must provide further data on safety and effectiveness from new clinical studies by 2026.
Estonian: Seetõttu soovitas inimravimite komitee jätkata ravimite kasutamist ennetuseks, kuid ettevõtted peavad 2026. aastaks esitama uutest kliinilistest uuringutest saadud lisaandmeid nende ohutuse ja tõhususe kohta.
English: These medicines are taken by mouth (as capsules, tablets, granules/powder for making up an oral mixture or drops), dissolved under the tongue (as tablets), inhaled through the nose (as a liquid) or given by injection into a muscle or under the skin.
Estonian: Neid ravimeid võetakse suu kaudu (kapslite, tablettide, suukaudse segu graanulite/pulbri või tilkadena), lahustatakse keele all (tabletid), inhaleeritakse nina kaudu (vedelik) või süstitakse lihasesse või naha alla.
English: Bacterial lysate medicines are made from bacterial cells that are broken down and are intended to stimulate the immune system to recognise and fight infections.
Estonian: Bakterilüsaadipõhised ravimid on valmistatud lagundatud bakterirakkudest ja nende eesmärk on stimuleerida immuunsüsteemi infektsiooni ära tundma ja sellega võitlema.
English: On 27 June 2019, EMA recommended that bacterial lysate medicines authorised for respiratory conditions should only be used for the prevention of recurrent respiratory infections, with the exception of pneumonia.
Estonian: 27. juunil 2019 soovitas EMA, et hingamisteede haiguste jaoks heakskiidetud bakterilüsaadipõhiseid ravimeid tuleks kasutada üksnes hingamisteede korduvate infektsioonide (v.a kopsupõletiku) ennetamiseks.
English: Although data are limited, the review found some evidence of effectiveness of these medicines in the prevention of recurrent respiratory tract infections and the safety profile is in line with what is expected for this type of product.
Estonian: Kuigi andmed on piiratud, leiti läbivaatamisel tõendeid nende ravimite efektiivsuse kohta hingamisteede korduvate infektsioonide ennetamisel ning nende ohutusprofiil on kooskõlas sellist liiki ravimite eeldatava ohutusprofiiliga.
English: • The prescribing information of the medicines is being updated with the new indication and a warning against use for prevention of pneumonia.
Estonian: • Ravimite määramise teavet uuendatakse uue näidustuse ja hoiatusega, et neid ei tohi kasutada kopsupõletiku ennetamiseks.
English: In the review, EMA's human medicines committee (CHMP) considered the results of clinical studies, data on side effects reported with these medicines, and advice from an expert group on infectious diseases.
Estonian: Kõnealuste ravimite läbivaatamisel võttis EMA inimravimite komitee arvesse kliiniliste uuringute tulemusi, ravimite kohta teatatud kõrvalnähtude andmeid ja infektsioonhaiguste eksperdirühma nõuannet.
English: Bacterial lysate medicines should not
Estonian: Bakterilüsaadipõhiseid ravimeid ei tohiks määrata hingamisteede
English: This followed a review that concluded that there are no robust data showing that these medicines are effective at treating existing respiratory infections, or for the prevention of pneumonia, therefore they should not be used for these purposes.
Estonian: Eelneva läbivaatamise käigus oli jõutud järeldusele, et puuduvad usaldusväärsed andmed, mis tõendaksid nende ravimite efektiivsust hingamisteede olemasolevate infektsioonide ravimisel või kopsupõletiku ennetamisel, mistõttu neid ei tohiks neil näidustustel kasutada.
English: • Bacterial lysate medicines should not be used to treat existing infections of the airways or to prevent pneumonia (a lung infection) because there are not enough data to show that they work for these uses.
Estonian: • Bakterilüsaadipõhiseid ravimeid ei tohi kasutada hingamisteede olemasolevate infektsioonide raviks ega kopsupõletiku ennetamiseks, sest ei ole piisavalt andmeid, mis tõendaksid, et need ravimid neil näidustustel toimivad.
English: • If you have an infection and are taking a bacterial lysate medicine to treat it, or if you are taking one of these medicines to prevent pneumonia, contact your doctor or pharmacist for advice on alternatives.
Estonian: • Kui võtate bakterilüsaadipõhist ravimit infektsiooni raviks või kopsupõletiku ennetamiseks, võtke ühendust oma arsti või apteekriga, et küsida nõu teiste ravivõimaluste kohta.
English: be prescribed for treatment of existing respiratory infections or for prophylaxis of pneumonia due to lack of efficacy data.
Estonian: olemasolevate infektsioonide raviks ega kopsupõletiku profülaktikaks efektiivsusandmete puudumise tõttu.
English: • The indications of bacterial lysate medicines have been restricted to prophylaxis of recurrent respiratory tract infections, with the exception of pneumonia.
Estonian: • Bakterilüsaadipõhiste ravimite näidustused piirati hingamisteede korduvate infektsioonide (v.a kopsupõletiku) profülaktikaga.
English: • Bacterial lysate medicines can continue to be used to prevent infections of the airways (except pneumonia) from coming back in patients who regularly get infections.
Estonian: • Bakterilüsaadipõhiseid ravimeid tohib jätkuvalt kasutada hingamisteede infektsioonide (v.a kopsupõletiku) ennetamiseks patsientidel, kellel esineb sageli infektsioone.
English: Oral use blister (alu/PVC/PCT FE)
Estonian: Suukaudne blister (Al/PVC/PCTFE)
English: 1 x 2 tablets (unit dose)
Estonian: 1 x 2 tabletti (üksikannus)
English: 90 mg Film-coated tablet
Estonian: 90 mg Õhukese polümeerikattega tablett
English: The vaccine helps to reduce the signs of these diseases.
Estonian: Vaktsiin aitab vähendada nende haiguste sümptomeid.
English: Further studies were carried out under laboratory conditions to confirm the other benefits of vaccination.
Estonian: Vaktsineerimise muude kasulike toimete kinnitamiseks tehti laboratoorseid lisauuringud.
English: Further information on Leucofeligen FeLV/RCP can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Lisateave vaktsiini Leucofeligen FeLV/RCP kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: One year after the initial vaccination a booster vaccination should be given.
Estonian: Üks aasta pärast esmast vaktsineerimist tuleb teha revaktsineerimine.
English: The European Medicines Agency decided that Leucofeligen FeLV/RCP's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et vaktsiini Leucofeligen FeLV/RCP kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise saab Euroopa Liidus heaks kiita.
English: The first injection is given when the kitten is about eight weeks old, and the second three or four weeks later.
Estonian: Esimene süst tehakse ligikaudu 8-nädalastele kassipoegadele ja teine 3-4 nädalat hiljem.
English: Because Leucofeligen FeLV/RCP is made up of two vaccines that have been available in the European Union (EU) since the 1980s (Feligen RCP and Leucogen), the company used data from studies carried out with these vaccines to support the use of Leucofeligen FeLV/RCP.
Estonian: Et Leucofeligen FeLV/RCP koosneb kahest vaktsiinist, mida on Euroopa Liidus turustatud alates 1980. aastatest (Feligen RCP ja Leucogen), kasutas ettevõte vaktsiini Leucofeligen FeLV/RCP kasutamise toetamiseks andmeid nende vaktsiinide uuringutest.
English: The most common side effects with Leucofeligen FeLV/RCP (which may affect up to 1 in 10 cats) are a moderate and short-lived local reaction (<2 cm) after the first injection which resolves without treatment within 3 to 4 weeks, raised body temperature (lasting 1 to 4 days), apathy (listlessness) and digestive disturbances.
Estonian: Vaktsiini Leucofeligen FeLV/RCP kõige sagedamad kõrvalnähud (võivad esineda kuni 1 kassil 10st) on pärast esimest süsti tekkiv mõõdukas ja lühiajaline paikne reaktsioon (<2 cm), mis taandub ilma ravita 3-4 nädala jooksul, kehatemperatuuri tõus (mis kestab 1-4 päeva), apaatia (loidus) ja seedehäired.
English: The FeLV protein used in the vaccine is not extracted from viruses but is made in a bacterium using ‘recombinant DNA technology'.
Estonian: Vaktsiinis kasutatavat kasside leukeemiaviiruse valku ei eraldata viirustest, vaid see valmistatakse bakteris rekombinant-DNA-tehnika abil.
English: The studies showed that Leucofeligen FeLV/RCP provided protection against the diseases listed above as measured by the presence of antibodies against the viruses in the vaccinated kittens' blood.
Estonian: Uuringud tõendasid, et Leucofeligen FeLV/RCP tagas eespool loetletud haiguste vastu kaitse, mida hinnati nende viiruste vastaste antikehade olemasolu põhjal vaktsineeritud kassipoegade veres.
English: The vaccine contains live feline viruses that have been attenuated (weakened) so they do not cause disease: feline calicivirus (strain F9), viral rhinotracheitis virus (strain F2) and feline panleucopenia virus (strain LR 72).
Estonian: Vaktsiin sisaldab kasside elusviirusi, mis on nõrgestatud, nii et need ei põhjusta haigusi: kasside kalitsiviirust (tüvi F9), viirusliku rinotrahheiidi viirust (tüvi F2) ja kasside panleukopeenia viirust (tüvi LR 72).
English: A laboratory study in which cats were exposed to feline leukaemia virus confirmed that following the first annual booster vaccination cats were protected for a three year period against leukaemia.
Estonian: Kasside leukeemiaviirusega kokku puutunud kasside laboriuuring kinnitas, et pärast esimest igaaastast revaktsineerimist püsis leukeemiavastane kaitse 3 aastat.
English: For more information about using Leucofeligen FeLV/RCP, see the package leaflet or contact your veterinarian or pharmacist.
Estonian: Kui vajate vaktsiiniga Leucofeligen FeLV/RCP toimuva ravi kohta lisateavet, lugege palun pakendi infolehte või pöörduge oma veterinaararsti või apteekri poole.
English: It also contains a protein of feline leukaemia virus (FeLV).
Estonian: Samuti sisaldab see kasside leukeemiaviiruse (FeLV) valku.
English: When a cat is given the vaccine, the immune system recognises the weakened viruses and the FeLV proteins as ‘foreign' and makes antibodies against them.
Estonian: Kui kassile antakse vaktsiini, peab looma immuunsüsteem nõrgestatud viirusi ja kasside leukeemiaviiruse valke võõraks ning tekitab nende vastu antikehi.
English: Other information about Leucofeligen FeLV/RCP
Estonian: Muu teave vaktsiini Leucofeligen FeLV/RCP kohta
English: What is Leucofeligen FeLV/RCP and what is it used for?
Estonian: Mis on Leucofeligen FeLV/RCP ja milleks seda kasutatakse?
English: The vaccine starts to protect against panleucopenia and leukaemia 3 weeks after the second injection and protection against calicivirosis and viral rhinotracheitis starts 4 weeks after the second injection.
Estonian: Kaitse panleukopeenia ja leukeemia vastu tekib 3 nädalat pärast teist süsti ning kalitsiviiruse ja viirusliku rinotrahheiidi vastu 4 nädalat pärast teist süsti.
English: Leucofeligen FeLV/RCP is available as two vials, one containing a white powder pellet and one containing a liquid.
Estonian: Vaktsiini Leucofeligen FeLV/RCP turustatakse kahe viaalina, millest üks sisaldab valget pulbripelletit ja teine vedelikku.
English: Leucofeligen FeLV/RCP should not be used in pregnant cats.
Estonian: Vaktsiini Leucofeligen FeLV/RCP ei tohi kasutada tiinetel kassidel.
English: Leucofeligen FeLV/RCP has been examined in two main ‘field' studies involving kittens aged eight to nine weeks.
Estonian: Vaktsiini Leucofeligen FeLV/RCP uuriti kahes peamises väliuuringus 8-9-nädalastel kassipoegadel.
English: Leucofeligen FeLV/RCP contains small amounts of the three weakened viruses as listed above and a protein from the outer layer of FeLV called ‘envelope p45 protein'.
Estonian: Leucofeligen FeLV/RCP sisaldab väikeses koguses kolme eespool nimetatud nõrgestatud viirust ja kasside leukeemiaviiruse väliskesta valku (viiruse kesta valku p45).
English: In addition, it reduced the excretion of feline viral rhinotracheitis viruses, prevented a fall in white blood cell counts in feline panleucopenia and prevented FeLV from remaining in the blood.
Estonian: Peale selle vähendas see kasside viirusliku rinotrahheiidi viiruse eritumist, ennetas leukopeeniat kasside panleukopeenia korral ja kasside leukeemiaviiruse püsimist veres.
English: In the future, the cat's immune system will be able to produce antibodies more quickly when it is exposed to the disease-causing forms of the viruses.
Estonian: Kui kassi immuunsüsteem puutub nende viiruste haigusi põhjustavate vormidega hiljem uuesti kokku, tekivad antikehad kiiremini.
English: The contents of the two vials are mixed together before use to make up a suspension for injection.
Estonian: Kahe viaali sisu segatakse kokku süstesuspensiooniks.
English: Its use is not recommended in cats nursing kittens.
Estonian: Seda ei ole soovitatav kasutada lakteerivatel kassidel.
English: An overview of Leucofeligen FeLV/RCP and why it is authorised in the EU
Estonian: Leucofeligen FeLV/RCP ülevaade ja Euroopa Liidus heakskiitmise põhjused
English: Leucofeligen FeLV/RCP is a vaccine.
Estonian: Leucofeligen FeLV/RCP on vaktsiin.
English: For the full list of side effects and restrictions with Leucofeligen FeLV/RCP, see the package leaflet.
Estonian: Vaktsiini Leucofeligen FeLV/RCP kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: FeLV/RCP only every 3 years, with annual revaccination in intervening years with the vaccine Feligen RCP to protect against calicivirosis, rhinotracheitis and panleucopenia.
Estonian: Vahepealsel ajal tehakse igal aastal revaktsineerimine vaktsiiniga Feligen RCP, et kaitsta kassi kalitsiviiruse, rinotrahheiidi ja panleukopeenia vastu.
English: It also prevents feline panleucopenia and persistent viraemia for feline leukaemia (the presence of feline leukaemia virus in the blood).
Estonian: Samuti ennetab see kasside panleukopeeniat ja kasside leukeemia korral püsivat vireemiat (kasside leukeemia viiruse esinemine veres).
English: How does Leucofeligen FeLV/RCP work?
Estonian: Kuidas Leucofeligen FeLV/RCP toimib?
English: Protection against leukaemia lasts for 3 years once a booster has been given and lasts for one year for calicivirosis and viral rhinotracheitis.
Estonian: Leukeemiavastane kaitse kestab 3 aastat pärast revaktsineerimist ning kalitsiviiruse ja viirusliku rinotrahheiidi kaitse 1 aasta.
English: Leucofeligen FeLV/RCP is given to kittens as two injections under the skin.
Estonian: Vaktsiini Leucofeligen FeLV/RCP manustatakse kassipoegadele kahe subkutaanse (nahaaluse) süstina.
English: The vaccine also contains aluminium hydroxide and extract of Quillaja saponaria as adjuvants (ingredients that strengthen the immune response).
Estonian: Samuti sisaldab vaktsiin immuunvastuse tugevdamiseks adjuvante (alumiiniumhüdroksiidi ja tšiili seebikoorepuu ekstrakti).
English: Therefore, older cats need revaccination with Leucofeligen
Estonian: Seetõttu vajavad vanemad kassid vaktsiiniga Leucofeligen FeLV/RCP revaktsineerimist ainult iga 3 aasta tagant.
English: What are the risks associated with Leucofeligen FeLV/RCP?
Estonian: Mis riskid vaktsiiniga Leucofeligen FeLV/RCP kaasnevad?
English: How is Leucofeligen FeLV/RCP used?
Estonian: Kuidas vaktsiini Leucofeligen FeLV/RCP kasutatakse?
English: Leucofeligen FeLV/RCP is a vaccine used to protect cats from eight weeks of age against the following diseases: feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus); feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus); feline panleucopenia (a serious illness causing bloody diarrhoea and a fall in white blood cell counts caused by a parvovirus); feline leukaemia (an illness affecting the immune system causing loss of appetite, weight loss, poor fur condition, fever, pale gums and diarrhoea caused by a retrovirus).
Estonian: kasside leukeemia (retroviirusest põhjustatud haigus, mis kahjustab immuunsüsteemi ning tekitab isutust, kaalulangust, karvastiku seisundi halvenemist, palavikku, kahvatuid igemeid ja kõhulahtisust).
English: What benefits of Leucofeligen FeLV/RCP have been shown in studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini Leucofeligen FeLV/RCP kasulikkus?
English: Leucofeligen FeLV/RCP received a marketing authorisation valid throughout the EU on <date of issue of the Marketing Authorisation>.
Estonian: Vaktsiini Leucofeligen FeLV/RCP müügiluba, mis kehtib kogu Euroopa Liidus, anti 25. juunil 2009.
English: Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States
Estonian: I lisa Ravimi nimetuste, ravimvormi, tugevuste, manustamisviisi, müügiloa hoidjate loetelu liikmesriikides
English: Sandoz Limited Frimley Business Park Frimley, Camberley Surrey GU16 7SR United Kingdom
Estonian: Ühendkuningriik Sandoz Limited Frimley Business Park Frimley, Camberley Surrey GU16 7SR
English: Luxembourg Laboratoire HRA Pharma 15, rue Béranger
Estonian: Luksemburg Laboratoire HRA Pharma 15, rue Béranger
English: Belgium Sandoz N.V. Telecom Gardens Medialaan 40
Estonian: Telecom Gardens Medialaan 40
English: HU-1103 Budapest Hungary
Estonian: HU-1103 Budapest
English: Czech Republic Gedeon Richter Plc.
Estonian: Ühendkuningriik Gedeon Richter Plc.
English: Luxembourg Medimpex UK Limited 127 Shirland Road
Estonian: Luksemburg Medimpex UK Limited 127 Shirland Road
English: Belgium Medimpex UK Limited 127 Shirland Road
Estonian: Ühendkuningriik Medimpex UK Limited 127 Shirland Road
English: Laboratorios Leon Farma SA Calle La Vallina S/N Poligono Industrial Navatejera Navatejera, Leon E-24008 Spain
Estonian: Laboratorios León Farma S.A. Calle La Vallina s/n Polígono Industrial Navatejera 24008 - Navatejera - León Spain
English: Levonorgestrel-containing emergency contraceptive medicinal products Member State (in EEA)
Estonian: Levonorgestreeli sisaldavate “hädaabi” kontratseptiivide nimekiri EL/EMP
English: Polígono Industrial Navatejera 24008 - Navatejera - León Spain
Estonian: Poligono Industrial Navatejera Navatejera, Leon E-24008
English: Czech Republic Laboratorios León Farma S.A. Calle La Vallina s/n
Estonian: Ühendkuningriik Laboratorios Leon Farma SA Calle La Vallina S/N
English: Overall the medicine was well tolerated, and appropriate measures to monitor and manage risks have been put in place.
Estonian: Üldiselt oli ravim hästi talutav ning kehtestatud on sobivad meetmed riskide jälgimiseks ja juhtimiseks.
English: What measures are being taken to ensure the safe and effective use of Cinqaero?
Estonian: Mis meetmed võetakse, et tagada Cinqaero ohutu ja efektiivne kasutamine?
English: The full EPAR for Cinqaero can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Cinqaero kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Cinqaero EMA/450050/2016
Estonian: Cinqaero EMA/450050/2016x
English: The recommended dose is 3 mg for each kg of bodyweight.
Estonian: Soovitatav annus on 3 mg kehamassi kg kohta.
English: Supportive data suggested that the benefit was maintained for up to two years.
Estonian: Täiendavate andmete kohaselt püsis ravitoime kuni kaks aastat.
English: Other information about Cinqaero
Estonian: Muu teave Cinqaero kohta
English: Flare-ups were seen in 32% of patients (151 out of 477) given Cinqaero compared with 50% (237 out of 476) of those given placebo.
Estonian: Ägenemisi täheldati 32%-l Cinqaerot saanud patsientidest (151 patsienti 477st), samas kui platseebot saanud patsientide seas esines ägenemisi 50%-l (237 patsienti 476st).
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Cinqaero's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Cinqaero kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.